Search
Carbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnIt was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.
Products: SICCAFLUID® 2.5 MG/G GEL OFTALMICOMirfentanil
go.drugbank.com/drugs/DB09175ExperimentalAt lower doses, it antagonizes the analgesic effects of alfentanil and substitutes for naloxone in morphine-treated monkeys; however, it also reverses naloxone-precipitated withdrawal in pigeons trained … At high doses, it exhibits analgesic activity which is not fully reversed by opioid antagonists, suggesting that the drug has both opioid and non-opioid mechanisms of action.
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Cositecan
go.drugbank.com/drugs/DB05806InvestigationalIt has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Drotrecogin alfa
go.drugbank.com/drugs/DB00055ApprovedWithdrawnIt is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Products: Xigris (5mg/vial)Phenylbutazone
go.drugbank.com/drugs/DB00812ApprovedVet approvedWithdrawnIt is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication).
Products: FENILBUTAZONA 200 MG TABLETASSodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] It is administered orally and is odorless, tasteless, and stable at room temperature.
Sofpironium
go.drugbank.com/drugs/DB19325Approved[L51103,L51108] It has also been available in Japan since 2020 under the brand name Ecclock.[L51103] … enhancing local efficacy by employing retrometabolic drug design, in which a molecule contains a metabolically sensitive moiety that promotes rapid metabolism to inactive metabolites after exerting activity at